the role of ev and pembrolizumab in the urothelial carcinoma treatment landscape
Published 1 year ago • 88 plays • Length 1:02Download video MP4
Download video MP3
Similar videos
-
0:49
evolving landscape of urothelial cancer treatment: erdafitinib or enfortumab vedotin?
-
13:47
ev-103: enfortumab vedotin and pembrolizumab in urothelial carcinoma
-
0:54
where do adcs fit in the treatment landscape of urothelial carcinoma?
-
6:02
ev-103: ev pembrolizumab as a promising first-line option for urothelial carcinoma
-
0:30
enfortumab vedotin plus pembrolizumab for advanced urothelial carcinoma
-
1:18
the role of enfortumab vedotin in urothelial cancer treatment
-
3:43
evaluating futibatinib, ev and dv with pembrolizumab in urothelial carcinoma
-
2:10
initial ev-103 results: enfortumab vedotin plus pembrolizumab for urothelial carcinoma
-
1:21
enfortumab vedotin and pembrolizumab vs platinum-based combination therapies for patients with muc
-
3:25
enfortumab vedotin with pembrolizumab for bladder cancer
-
2:43
pembrolizumab: defining standards of care in urothelial cancer
-
3:38
breakthroughs in urothelial cancer treatment at esmo 2023
-
1:17
recent advances in the treatment of upper tract urothelial carcinoma
-
3:45
fierce-22 trial: vofatamab with pembrolizumab for urothelial carcinoma
-
0:46
molecular markers guiding treatment approaches in bladder cancer
-
4:31
current obstacles in the treatment of urothelial carcinoma
-
4:22
checkmate 274 & ev-301: highlights in uc from asco gu
-
1:22
key clinical trials in urothelial carcinoma at esmo 2021
-
6:01
ev-201, ev-301 and unite: enfortumab vedotin in advanced urothelial cancer